Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2007 Jan;64(1):174-85.
doi: 10.1016/j.socscimed.2006.08.023. Epub 2006 Oct 2.

Variant Creutzfeldt-Jakob disease and the Canadian blood system after the tainted blood tragedy

Kumanan Wilson  1 , Ian Graham, Maura Ricketts, Christopher Dornan, Andreas Laupacis, Paul Hebert
Affiliations

Variant Creutzfeldt-Jakob disease and the Canadian blood system after the tainted blood tragedy

Kumanan Wilson et al. Soc Sci Med. 2007 Jan.

Abstract

The transfusion transmission of hepatitis C and HIV to thousands of Canadian blood recipients was one of this country's largest public health catastrophes. In response to this crisis, and in an effort to prevent such a tragedy from occurring again, the Canadian blood system has undergone substantial reform. Variant Creutzfeldt-Jakob (vCJD) disease was the first infectious threat faced by the blood system since undergoing reform. The response at the time to this risk provides insights into the Canadian blood system's new approach to infectious threats. Our analysis of the decision-making concerning vCJD identifies two dominant themes characterizing the new blood system's approach to safety: (1) the adoption of a precautionary approach to new risks which involves taking action in advance of definitive evidence, and (2) risk aversion amongst policy makers, which has contributed to the adoption of safety measures with comparatively high cost-effectiveness ratios. Overall the principles governing the new blood system have contributed to the system both providing protection against emerging infectious risks and regaining the confidence of the public and recipients. However, the current set of policy factors will likely contribute to increasingly risk-averse policy making that will contribute to continued increases in the cost of the blood system. The challenge the blood system now faces is to find the appropriate balance between maximizing safety and ensuring the system remains affordable.

PubMed Disclaimer

Figures

Fig. 1
Fig. 1
Lomas policy analysis framework. A schematic of the contextual influences on the decision-making process.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. Aach R.D., Szmuness W., Mosley J.W., Hollinger F.B., Kahn R.A., Stevens C.E. Serum alanine aminotransferase of donors in relation to the risk of non-A, non-B hepatitis in recipients: The transfusion-transmitted viruses study. New England Journal of Medicine. 1981;304(17):989–994. - PubMed
    1. Alter H.J., Purcell R.H., Holland P.V., Alling D.W., Koziol D.E. Donor transaminase and recipient hepatitis. Impact on blood transfusion services. Journal of The American Medical Association. 1981;246(6):630–634. - PubMed
    1. AuBuchon J.P., Petz L.D. Making decisions to improve transfusion safety. In: AuBuchon J., Petz L., Fink A., editors. Policy alternatives in transfusion medicine. AABB Press; Bethesda, MD: 2001.
    1. Bayer Advisory Council on Bioethics . Bayer Advisory Council on Bioethics; Ottawa: 1998. Creutzfeldt–Jakob disease, blood and blood products: A bioethics framework.
    1. Bayer, R., & Feldman, E.A. (1999). Understanding the blood feuds. In F. E. A., B. R. (Eds.), Blood feuds. Aids, blood, and the politics of medical disaster. Oxford: Oxford University Press.

Publication types